Nouveau Life Pharmaceuticals, Inc.
Other OTCTotal Valuation
Nouveau Life Pharmaceuticals, Inc. carries a market capitalization of 90,000.00, placing it among publicly traded companies globally. Its enterprise value stands at 5.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 90,000.00 |
| Enterprise Value | 5.18M |
Share Statistics
Nouveau Life Pharmaceuticals, Inc. currently has 30.11M shares outstanding.
| Shares Outstanding | 30.11M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.63 |
| P/TBV Ratio | -13.51 |
| P/FCF Ratio | -251.66 |
| P/OCF Ratio | -237.81 |
Financial Position
Nouveau Life Pharmaceuticals, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | 151.19 |
| Debt / EBITDA | -0.27 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -39.31 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Nouveau Life Pharmaceuticals, Inc.'s stock has gained approximately 9900% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 9900% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -235,593.00, while operating income came in at -503,315.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -503,315.00 |
| Pretax Income | N/A |
| Net Income | -503,315.00 |
| EBITDA | -235,593.00 |
| EBIT | -503,315.00 |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
Nouveau Life Pharmaceuticals, Inc. holds 347.00 in cash and equivalents against 64,536.00 in total debt, resulting in a net debt position of 64,189.00. Total book value stands at -3.13M, with working capital of -899,219.00 providing operational flexibility.
| Cash & Cash Equivalents | 347.00 |
| Total Debt | 64,536.00 |
| Net Debt | 64,189.00 |
| Equity (Book Value) | -3.13M |
| Book Value Per Share | -0.10 |
| Working Capital | -899,219.00 |
Cash Flow
Nouveau Life Pharmaceuticals, Inc. produced -21,516.00 in operating cash flow over the past twelve months. After subtracting -1,184.00 in capital expenditures, free cash flow totaled -22,700.00 - equivalent to 0.00 per share.
| Operating Cash Flow | -21,516.00 |
| Capital Expenditures | -1,184.00 |
| Free Cash Flow | -22,700.00 |
| FCF Per Share | 0.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.32 |
| FCF Yield | -0.40 |
Scores
Nouveau Life Pharmaceuticals, Inc. posts an Altman Z-Score of -6.86, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.86 |